Daxor Corporation announced new data demonstrating the clinical utility of the BVA-100 blood test in patients with non-traumatic subarachnoid hemorrhage (nSAH) presented at the virtual NeuroCritical Care Society (NCS) 19th Annual Meeting. The study titled, ?The Influence of Blood Volume Analysis on the Clinical Management of Non-Traumatic Subarachnoid Hemorrhage,? surveyed whether intravascular volume assessments would influence clinical decision making in nSAH. The data showed 69% responded with different management strategies after being provided with BVA results. Prior research presented at NCS in 2020 titled the ?Blood Volume Analysis in the Management of Volume Status in Non-Traumatic Subarachnoid Hemorrhage,? studied whether BVA would change clinical practice guidelines for management of nSAH to prevent Delayed Cerebral Ischemia (DCI) during the high-risk periods. Of the BVA tests completed, 54% resulted in a change of treatment management after interpretation of the BVA test results. ?These new data further demonstrate that Daxor?s unique blood volume measurement helps guide physicians to effectively determine treatment options to manage fluid derangements for these critically-ill patients and is the driver of this test for standard clinical practice.? Prior data in the area of Surgical ICU Management showed a similarly high level of BVA-100 tests resulting in a change of treatment strategy. In a randomized control trial (RCT) published in the journal Shock, the BVA-100 test has shown to reduce ICU mortality by 66% (P=0.03) and reduce ventilator days in patients suffering predominantly from acute respiratory distress syndrome and septic shock. Additionally, the analysis showed 44% of BVA test results led to a change in treatment strategy (P=0.004) that care teams would not have performed absent the data from the BVA volume status measure.